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Anti-IL-5 monoclonal antibody (mepolizumab) reduces baseline bronchial mucosal eosinophils and deposition of
extracellular matrix proteins in the reticular basement membrane in mild asthma. Here we report the effect of anti-
IL-5, in the same patients, on allergen-induced eosinophil accumulation, tenascin deposition (as a marker of repair
and remodelling) and the magnitude of the late-phase allergic cutaneous reaction. Skin biopsies were performed in
24 atopic subjects at allergen- and diluent-injected sites before 6 and 48 h after, three infusions of a humanized,
monoclonal antibody against IL-5 (mepolizumab) using a randomized double-blind, placebo-controlled design.
Anti-IL-5 signiﬁcantly inhibited eosinophil inﬁltration in 6 h and 48 h skin biopsies as well as the numbers of
tenascin immunoreactive cells at 48 h. In contrast, anti-IL-5 had no signiﬁcant effect on the size of the 6 or 48 h late-
phase cutaneous allergic reaction. This study (a) suggests that eosinophils are unlikely to cause the redness,
swelling, and induration characteristic of the peak (6 h) late-phase cutaneous allergic reaction and (b) shows that
decreases in tenascin positive cells at 48 h correlates with reduction of eosinophils, so providing further evidence
of involvement in remodelling processes associated with allergic inﬂammation.
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In addition to their role as pro-inflammatory cells in allergy,
asthma eosinophils are also involved in certain repair and
fibrotic processes consequent to allergic inflammation. For
example, in the skin of atopic subjects, eosinophil-derived
fibrogenic factors (transforming growth factor-b (TGF-b1)
and interleukin (IL)-13) were temporally associated with
fibroblast-associated tenascin and procollagen-I immuno-
reactivity, and the formation of a-smooth muscle (SM)
actinþmyofibroblasts, following local allergen challenge
(Phipps et al, 2002). In addition the specific reduction of
eosinophils in asthmatic airways at baseline by intravenous
infusions of an anti-IL-5 monoclonal antibody decreased the
deposition of the extracellular matrix (ECM) proteins,
tenascin, lumican, and procollagen III, within the reticular
basement membrane (Flood-Page et al, 2003b).
IL-5 is essential for the terminal differentiation of the
committed eosinophil precursor (Sanderson, 1992). It is also
involved in eosinophil migration and priming (Sehmi et al,
1992) and prolongs the survival of the cell in tissues
(Rothenberg et al, 1989). More recently monoclonal anti-
bodies against IL-5 have been prepared and administered
as a single intravenous infusion to both mild atopic (Leckie
et al, 2000), as well as chronic, severe asthmatics (Kips et al,
2003). These have produced no appreciable effects on
either the late asthmatic reaction, airway hyperresponsive-
ness or other clinical outcomes including lung function.
However, although anti-IL-5 almost totally ablated eosino-
phils in the blood and sputum (Leckie et al, 2000), tissue
eosinophils were reduced rather than depleted (Flood-Page
et al, 2003a), possibly as a result of downregulated IL-5Ra
expression of airway eosinophils (Liu et al, 2002; Gregory
et al, 2003).
In this study, we have measured eosinophils, tenascin,
and the size of the late-phase reaction (LPR) in allergen-
challenged skin sites before and after anti-IL-5. The
cutaneous LPR, elicited in atopic subjects, is characterized
by an edematous, red, and slightly indurated swelling that
peaks 6–9 h after intradermal allergen challenge. The LPR
is often considered as a model of allergic inflammation
since it is associated with local infiltration by various cell
types including eosinophils, basophils, and neutrophils.
The eosinophil in particular has been considered as an
important effector cell in producing the macroscopic
appearance of the LPR possibly through the release of lipid
mediators such as cysteinyl leukotrienes (Reshef et al,
1989; Zweiman et al, 1991; Wardlaw et al, 1995). Although
increases in the size of the LPR accompanies increases in
the numbers of eosinophils up to 6 h after allergen injection,
thereafter the cell persists in tissues whereas the LPR
declines fairly rapidly (Phipps et al, 2002). For this reason we
were interested to study the effect of reduction or depletion
of eosinophils, by anti-IL-5, on the magnitude of the
allergen-induced LPR.
Abbreviations: APAAP, alkaline phosphatase anti-alkaline phos-
phatase; ECM, extracellular matrix; FEV1, forced expiratory volume
in 1 s; IL, interleukin; LPR, late-phase reaction; MBP, major basic
protein; TGF-b, transforming growth factor-b
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In this study, we performed skin biopsies 6 and 48 h after
cutaneous allergen challenge (from the same patients
described as previously by Flood-Page et al, 2003b) before
and after the infusion of an anti-IL-5 monoclonal antibody.
We chose the 6 h time point as optimal for studying the
effect of eosinophil depletion on the LPR since in time-
course studies up to 72 h this was shown to be the peak
of the characteristic redness and swelling (Phipps et al,
2002). A 48 h biopsy time point was chosen to enable us to
determine whether this procedure affected the later
expression of a marker of repair (as previously shown for
tenascin) (Phipps et al, 2002).
Results
Anti-IL-5 reduces eosinophil inﬁltration but does not
effect the size of the cutaneous LPR Figure 1 shows the
skin Congo redþ eosinophil counts of biopsies taken from
the diluent- and allergen-injected sites in subjects receiving
anti-IL-5 or placebo. At 6 h after intradermal allergen
challenge there was no significant difference (pre vs post)
in the numbers of skin eosinophils in subjects receiving
placebo; however, the counts were significantly less (pre vs
post, p¼0.002) in those receiving intravenous anti-IL-5
monoclonal antibody, with a between-group difference of
p¼0.0015. This represented a median change in eosinophil
numbers at 6 h of 83% for anti-IL-5 and þ33% for
placebo. At 48 h after intradermal allergen challenge, there
was no significant difference (pre vs post) in the numbers of
skin eosinophils in the placebo group but the counts were
significantly less (pre vs post, p¼0.003) in those receiving
anti-IL-5. The between-group difference at 48 h was
p¼0.0025. The mean eosinophil counts of all the diluent-
injected sites was less than 2 cells per mm2. Similar results
were obtained with anti-MBP with a between-group
difference at 6 h (anti-IL-5 vs placebo) of p¼ 0.01 (data
not shown). The number of degranulating cells was also
counted (Fig 2). At 6 h after intradermal allergen challenge
there was no significant difference (pre vs post) in the
numbers of degranulating eosinophils in subjects receiving
placebo; however, the counts were significantly less (pre vs
post, p¼0.001) in those receiving intravenous anti-IL-5
monoclonal antibody, with a between-group difference of
p¼0.029. At 48 h after intradermal allergen challenge, there
was no significant difference (pre vs post) in the numbers of
degranulating skin eosinophils in the placebo group but the
counts were significantly less (pre vs post, p¼0.0117) in
those receiving anti-IL-5.
As previously shown (Ying et al, 1999), there were also
significant allergen-induced increases in BB1þbasophils,
elastaseþneutrophils and CD4þT cells at both time points
but their numbers were unaffected by infusions of anti-IL-5
(data not shown).
In contrast, administration of anti-IL-5 (or placebo) had
no significant effect on the 6 h late-phase cutaneous
reaction (Fig 3). The magnitude of the 6 h LPR was similar
to that previously observed (Frew and Kay, 1988; Ying et al,
1999; Phipps et al, 2002). In the majority of subjects, in both
the active and placebo group, the 48 h LPR had, with the
exception of a few individuals, largely resolved. But in five
individuals who had a small waning 48 h reaction, anti-IL-5
appeared to have a small, but NS, inhibitory effect
(individual data not shown).
Anti-IL-5 deplete tenascin-positive cells in 48 h biop-
sies Figure 4 shows the numbers of tenascinþ fibroblast-
like cells from biopsies taken from diluent-and allergen-
injected sites pre- and post-treatment. Tenascinþ cells
were predominantly located in the lower dermis and were
identified morphologically as fibroblasts, appearing fusifor-
mic in shape with elongated nuclei. There were negligible
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Figure1
Effect of anti-IL-5 mAb on allergen-induced eosinophil infiltration.
Eosinophil numbers are expressed as the number of Congo redþ cells
(mean  SEM) per square millimeter of skin biopsy (n¼ 11–13). There
was no significant between-group difference (anti-IL-5 vs placebo) in
the allergen-induced increases in eosinophils before treatment at either
6 or 48 h (P¼ 0.1858 and 0.31, respectively). The differences between
pre- and post-treatment (active or placebo) were analyzed by Wilcoxon
signed-rank test. The Mann–Whitney U test was used for intergroup
comparison. IL, interleukin; mAb, monoclonal antibody.
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Figure2
Effect of anti-IL-5 mAb on the numbers of MBPþdegranulating
eosinophils after allergen-challenge. Degranulating MBPþeosino-
eosinophil numbers are expressed as the number of cells (mean
 SEM) per square millimeter of skin biopsy (n¼ 11–13). The
differences between pre- and post-treatment (active or placebo) were
analyzed by Wilcoxon signed-rank test. The Mann–Whitney U test was
used for intergroup comparison. IL, interleukin; mAb, monoclonal
antibody; MBP, major basic protein.
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numbers of tenascinþ cells (mean o1 cell per mm2) at
diluent-injected sites. At 6 h after intradermal allergen
challenge there was no significant difference (pre-placebo
vs post-placebo, or pre-anti-IL-5 vs post-anti-IL-5) in the
numbers of fibroblast-like tenascinþ cells. The between-
group difference at 6 h was also NS. At 48 h, however, the
counts were significantly less in those receiving intravenous
anti-IL-5 monoclonal antibody (pre vs post, p¼ 0.003), but
not in those receiving placebo. The between-group differ-
ence at 48 h was also significant (p¼0.0256). There was
also a highly significant correlation between the D change in
eosinophils and the D change in tenascinþ cells in those
receiving anti-IL-5 (p¼0.0005; Fig 5). Examples of Congo
redþ eosinophils and immunostaining for tenascinþ cells,
pre- and post-anti-IL-5, are shown in Fig 6.
Discussion
This study shows that selective reduction of tissue
eosinophils (as opposed to blood and sputum eosinophils)
does not significantly affect the magnitude of the allergen-
induced LPR. Although eosinophil accumulation was not
completely abrogated by anti-IL-5, these data suggest,
nevertheless, that eosinophils are unlikely to be essential for
the development of the LPR at its peak (i.e. 6 h). It was
previously shown that administration of anti-IL-5 had no
effect on the late asthmatic reaction or airway hyperrespon-
siveness (Leckie et al, 2000) although in that report it was
not ascertained whether the intervention actually depleted
eosinophils in the relevant tissue, i.e. the bronchial mucosa.
Indeed, it appears that whereas on the one hand anti-IL-5
will prevent the allergen-induced increase in eosinophils in
the skin of (otherwise normal) atopics (Fig 1) (where there
are virtually no eosinophils at baseline), this treatment, even
when administered on several occasions, over several
weeks, had only a partial effect (median depletion of 55%)
on baseline eosinophils in the bronchial mucosa (Flood-
Page et al, 2003a), which in asthmatics is already mildly
inflamed and contains appreciable numbers of eosinophils
even when ‘‘unprovoked’’ (Azzawi et al, 1990).
The precise mechanisms involved in the redness,
swelling, and slight induration that characterizes the peak
(6–9 h) late-phase skin response remains unclear. Although
this study indicates that eosinophils do not appear to be
essential, other cell types such as the basophil may be
involved. Basophils are a rich source of mediators including
histamine and cysteinyl leukotrienes (Church et al, 1997;
Macfarlane et al, 2000) and respond to allergen via IgE
bound to FceR1. Furthermore, the peak of the late-phase
response is usually between 6 and 24 h, at which time
basophil numbers are maximal at skin sites after allergen
challenge (Ying et al, 1999). Although IL-5 is also believed to
act as a terminal basophil differentiation factor (Denburg
ANTI-IL-5 PLACEBO
ns
ns
60
40
20
0
Cu
ta
ne
ou
s 
LP
R 
(m
m)
Dil 6 48
Time(h)
60
40
20
0
Cu
ta
ne
ou
s 
LP
R 
(m
m)
Dil 6 48
Time(h)
PRE
POST
Figure 3
Effect of anti-IL-5 mAb on the size of the allergen-induced
cutaneous LPR. Data represent mean  SEM; n¼ 11–13. The differ-
ences between pre- and post-treatment (active or placebo) were
analyzed by Wilcoxon signed-rank test. The Mann–Whitney U test was
used for intergroup comparison. IL, interleukin; mAb, monoclonal
antibody; LPR, late-phase reaction.
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Figure 4
Effect of anti-IL-5 mAb on allergen-induced tenascin expression.
The results are expressed as the number of tenascinþ cells (mean
 SEM) per square millimeter of skin biopsy (n¼ 11–13). There were
no significant between-group differences (anti-IL-5 vs placebo) in the
allergen-induced increases in tenascinþ cells before treatment at either
6 or 48 h (P¼ 0.3402 and 0.1315, respectively). The differences
between pre- and post-treatment (active or placebo) were analyzed by
Wilcoxon signed-rank test. The Mann–Whitney U test was used for
intergroup comparison. IL, interleukin; mAb, monoclonal antibody.
Figure5
Correlation between the change in tissue eosinophils and change
in tenascinþcells after allergen challenge. The results are ex-
pressed as the D change in the number of eosinophils and the D
change in the number of tenascinþ cells (mean  SEM) per square
millimeter of skin biopsy (n¼ 11), following active treatment at the 48 h
time point. Correlations were obtained by Spearman’s method with
correction for tied values.
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et al, 1991), however, anti-IL-5 did not appear to affect the
numbers of infiltrating BB1þbasophils as identified either in
6 or 48 h skin biopsies (data not shown).
We were able to study the effects of anti-IL-5 on the LPR
at both the 6 and 48 h time points. It was previously shown
that the cutaneous LPR plateaus at 6–9 h whereas the peak
of eosinophils is variable between 6 and 24 h (Phipps et al,
2002). Thus the 6 h time point was optimal for studying the
relationship between eosinophils and the LPR, and as
previously shown, tenascinþ cells peaked at 48 h (Phipps
et al, 2002). The findings presented here are in agreement
with our previous observations of a dissociation between
eosinophil numbers and the size of the cutaneous reaction
(Phipps et al, 2002). Thus, whereas increases in eosinophil
numbers and the size of the LPR increased in parallel at the
1, 3, 6, and 24 h time points, thereafter eosinophils persist in
the tissue whereas the LPR rapidly resolves. In previous
studies, we showed that tissue eosinophils persisted for up
to 7 d but that the LPR was usually absent at 72 h (Ying
et al, 1999). Although the 6 h LPR was not affected by anti-
IL-5, five of the 11 individuals who had a small positive 48 h
LPR before anti-IL-5 treatment showed a reduction in their
LPR after treatment (Fig 3). Therefore, we cannot totally
exclude a role for the eosinophil at later time points,
however, classically the LPR refers to events observable
between 6 and 9 h.
A previous publication showed that eosinophil granule
protein deposition was prominent in the cutaneous LPR in
atopics, peaking between 4 and 8 h and persisting for 48 h
(Leiferman et al, 1990). Our study largely confirms these
findings. Degranulating MBPþ cells were observed in
almost equal numbers at 6 and 48 h in the placebo group
(pre and post) (Fig 2). After anti-IL-5 there were very few
degranulating cells at either time point. Furthermore, the
LPR is transient and wanes after 6–9 h (Phipps et al, 2002)
whereas, as stated, eosinophils and eosinophil products
persist for many hours and days. This makes it unlikely that
degranulating eosinophil products were contributing to the
6 h LPR although in some subjects there may be a small
eosinophil component to the waning 48 h response. It is
also noteworthy that, although eosinophil-derived basic
proteins are toxic for various cell types, including epithelial
cells, there is no evidence that they cause the vasodilation
and edema which characterizes the late-phase skin
response.
Anti-IL-5 had a slightly more marked effect on the
number of Congo redþ eosinophils than MBPþ cells. But
basophils also contain small amounts of MBP (Ackerman
et al, 1983).
Our second novel finding was the demonstration that
reduction of the allergen-induced eosinophil response
abrogated the 48 h increase in tenascinþ fibroblast-like
cells (Fig 4). Furthermore, there was a correlation between
the decrease in the numbers of eosinophils and the
decrease in the numbers of tenascinþ cells (Fig 5) and so
supports the view that upregulation of tenascin expression
by fibroblast-like cells following intradermal allergen chal-
lenge is partly under the control of infiltrating eosinophils
presumably through the release of fibrogenic factors such
as TGF-b. This is in keeping with our recent study show-
ing, in these same patients, decreased deposition of the
ECM proteins, tenascin, lumican, and to a lesser extent,
procollagen III, within the reticular basement membrane,
together with decreased numbers of TGF-bþ eosinophils in
the bronchial mucosa, after anti-IL-5 treatment (Flood-Page
et al, 2003b). Due to limitations of available tissue, we were
unable to confirm that the numbers of TGF-bþ eosinophils
were similarly decreased in the skin. Although, in our
previous study in the skin (Phipps et al, 2002) we had shown
that allergen induces the upregulation of other markers of
remodelling (i.e. a-SM actinþmyofibroblasts and procolla-
gen-Iþ cells), we were only able to show, in this study, an
effect of anti-IL-5 on tenascinþ cells. There are likely to be
many other sources of TGF-b and other fibrogenic growth
Figure 6
Effect of anti-IL-5 mAb on tissue
eosinophils and tenascinþcells Ex-
amples of Congo redþeosinophils and
immunostaining for tenascinþ cells,
pre- and post-anti-IL-5 (magnification
 200).
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factors (such as macrophages, T cells and neutrophils),
however, which would not be affected by the infusions of
anti-IL-5. Thus, the precise contribution of eosinophils (as
compared to other cell types) to repair and remodelling
processes must await further investigation.
Tenascin is a highly regulated member of the matricellular
family that is expressed during development, growth, and in
response to injury (Erickson and Bourdon 1989; Ruegg et al,
1989). In asthmatic airways the balance of the ECM proteins
is altered and the deposition of tenascin, together with
several other ECM proteins, is increased (Laitinen et al,
1997). The ECM not only forms a network of molecules that
support the airways, it is also a dynamic network that has
the capacity to influence cellular function. Tenascin has
been demonstrated to act as a permissive substance that
can prevent or allow cell migration (Treasurywala and
Berens, 1998) and we have previously shown a significant
upregulation of tenascin expression within fibroblast-like
cells, at the vascular SM basement membrane and in and
around bundles of SM in response to intradermal allergen
challenge (Phipps et al, 2002). It is possible that tenascin, in
conjunction with other proteins, facilitates cellular migration
through the interstitial matrix towards sites of tissue injury
and thus may play a role in remodelling.
The late-phase skin reaction is often regarded as a
model of atopic dermatitis because in both situations the
histopathological picture is of an eosinophilic cell mediated
hypersensitivity reaction. In atopic dermatitis, however,
there is relatively little deposition of collagen and ECM
proteins. Thus a single allergen challenge in otherwise
healthy normal skin is unlikely to lead to marked remodelling
(Ying et al, 1999; Phipps et al, 2002). Nevertheless, it is
associated with type I collagen deposition and expression
of the pro-fibrotic cytokines IL-11 and IL-17 (Toda et al,
2003) and, as such, the late-phase skin reaction could serve
as a general model for events associated with the laying
down of collagen and other ECM proteins, not only in skin
disease but also in asthma. In the airways of asthmatics, for
instance, cells of the epithelial–mesenchymal trophic unit
are now recognized as active participants in the inflamma-
tory process (Holgate et al, 2000). Although this remodelled
phenotype is generally believed to be the result of chronic
inflammation, our recent findings in the skin (Phipps et al,
2002) and those of Gizycki et al (1997) in the airways
suggest that tissue remodelling is an acute/subacute
process, resulting from allergen-induced interactions be-
tween eosinophils and other inflammatory cells with
mesenchymal cells.
In a mouse model of atopic asthma, Blyth et al (2000)
demonstrated a reduction in the development of subepithe-
lial reticular basement membrane thickness by treatment
with anti-IL-5 at the time of allergen challenge. In agreement
with the reported effects of anti-IL-5 on subepithelial
basement membrane thickening in the airways (Flood-Page
et al, 2003b), we demonstrated that the selective depletion
of eosinophils in response to intradermal challenge led to a
significant reduction in the numbers of tenascinþ cells at
48 h. Although in a hamster model of incisional wound
healing depletion of eosinophils with anti-IL-5 accelerated
the rate of wound closure by re-epithelialization (Yang et al,
1997), this study may simply reflect the pleiotropic activity
of TGF-b on different components of the healing res-
ponse. Smad-3 (a downstream signal transducer for TGF-b)
heterozygous mice also demonstrate accelerated re-epithe-
lialization compared with wild-type mice (Shipley et al, 1986;
Ashcroft et al, 1999), an effect mediated by removal of the
inhibitory action of TGF-b on keratinocyte chemotaxis and
proliferation (Sehmi et al, 1992). Although together these
studies suggest that eosinophils, in response to injury,
signal to and activate epithelial and mesenchymal cells, it
remains to be determined whether eosinophil-induced
tissue remodelling is beneficial or detrimental to the host.
The observed effect of anti-IL-5 on tenascin may have
been via a direct effect on fibroblasts, or other mesench-
ymal cells, rather than through a reduction of tissue
eosinophils; however, there are no data reporting enhanced
synthesis of ECM protein by IL-5 and fibroblasts do not
appear to express the IL-5Ra chain (T.-T. Ou and S. Phipps,
unpublished). Furthermore, there was a direct correlation
between the D changes in eosinophils and changes in
tenascinþ cells in those receiving anti-IL-5 (Fig 5).
In conclusion our data suggest that eosinophils are
unlikely to be essential for the swelling and induration that
characterizes the late-phase skin reaction at its peak
(i.e. 6–9 h) and that they may play a role in remodelling
processes associated with allergic inflammation.
Materials and Methods
Volunteers for anti-IL-5 study The study was approved by the
ethics committees of the Royal Brompton and Harefield NHS Trust
and the London Chest Hospital, and was performed in accordance
with the guidelines of the Declaration of Helsinki. All volunteers
gave informed consent prior to participation in the study. 24
volunteers were recruited with a history of mild asthma, with an
forced expiratory volume in 1 s (FEV1) of  70% of the normal
value for age and height and within an 18–55 y age range. All
volunteers were atopic defined by a positive skin prick test to one
or more aeroallergens (Dermatophagoides pteronyssinus, cat, dog,
and mixed grass and tree pollen (all ALK, Horsholm, Denmark)) and
were well controlled with short-acting b2 agonist alone, had no
history of worsening asthma or upper respiratory tract infection
in the preceding 4 wk, and had not taken inhaled or oral
corticosteroids, or other anti-inflammatory drugs or anti-histamines
in the preceding 8 wk. There was documented airway hyper-
responsiveness as shown by a provocative concentration causing
a 20% fall in FEV1 to histamine of  4.0 mg per mL. All volunteers
were non-smokers for at least the preceding 6 mo with no more
than a 10-pack year lifetime smoking history.
Study design and processing of specimens This was a two-
center double-blind, placebo-controlled, parallel group study
designed to evaluate the effects of an anti-IL-5 monoclonal
antibody on baseline bronchial mucosal and bone marrow
eosinophils and allergen-induced skin eosinophils. The results of
studies on the effect of treatment on blood, bronchial, and bone
marrow eosinophils has been reported elsewhere (Flood-Page
et al, 2003a, b). Volunteers were randomized to receive either
mepolizumab (750 mg) or placebo, administered as an intravenous
infusion over 30 min. The second and third infusions of the study
drug were given 4 and 8 wk after the first infusion. Skin biopsies
were obtained 2 d before the first infusion of study medication and
between 1 and 2 wk after the third infusion. All injections were
performed with a 29-gauge needle and a 0.5 mL plastic syringe.
Using this method, 30 biological units of either grass, house dust
mite, cat, or dog allergen was injected intradermally into two sites
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on the extensor aspect of the forearms of each subject. The size of
the cutaneous reaction was determined at 6 and 48 h by measuring
resistance to the movement of a sharpened pencil and expressed
as the mean diameter (mm) as previously described (Ying et al,
1999). There were no appreciable differences in the size of the
late-phase skin responses between the various allergens used.
An additional site was injected with a similar volume of diluent.
Macroscopic responses were measured at 6 and 48 h and
permanent sticky tape records of the outlines of the responses
made. A 4 mm disposable biopsy punch was used to take a biopsy
from the center of the reaction at 6 and 48 h after using 1% plain
lignocaine for local anesthesia. The control site injected with
diluent was biopsied at 6 h. In this way, each patient served as his/
her control. Tissue biopsies were immediately fixed in 4%
paraformaldehyde and washed in 15% PBS-buffered sucrose
(Sigma, Poole, UK), embedded in OCT (optimal cutting tempera-
ture), then snap-frozen in isopentane precooled in liquid nitrogen.
Cryostat sections (o8 mm) were cut from biopsies, mounted onto
Superfrost Plus slides, dried overnight at 371C, then stored with
silica gel at 801C until use (all VWR, Dagenham, UK unless
stated).
Histochemistry and immunohistochemistry Eosinophil accu-
mulation was determined by Congo red, a selective stain for
eosinophils in tissue sections from the skin as described previously
(Ying et al, 2002). Briefly, sections were washed in PBS for 5 min
then incubated in 0.5% Congo red (Sigma) in ethanol/0.1 M glycine
(1:1) for 5 min at room temperature. The slides were then rinsed in
70% ethanol until the background became clear, then mounted in
glycergel (Dako, Cambridge, UK). The alkaline phosphatase anti-
alkaline phosphatase (APAAP) technique was used to enumerate
cells immunoreactive to a monoclonal antibody (mAb) against CD4,
eosinophil major basic protein (MBP), neutrophil elastase, basophil
BB1 (a generous gift from Dr A. Walls, University of Southampton,
UK), and tenascin (Caltag-Medsystems, Towcester, UK). The APAAP
technique, with source of reagents, was performed as described
previously (Ying et al, 1999). Tissue sections were developed with
fast red (Sigma) as chromogen for signal visualization (Dako). Cells
were counter stained with Harris’ Hematoxylin (VWR) and mounted
in glycergel. Positive cells stained red after development with fast
red. Substitution of the primary antibody with an irrelevant isotype-
matched antibody of the same species was used as a negative
control. One biopsy specimen from each time point was evaluated
from each patient.
Quantitation and statistical analysis Slides were encoded and
counted in a blinded fashion using an Olympus microscope
(Olympus Optical Co., London, UK). The whole section was
counted and the total number of single positive cells expressed
as cell per square millimeter of biopsy. Data were analyzed using a
statistical software package (Minitab Release 13.1, Minitab, State
College, Pennsylvania). Non-parametric statistics were used
throughout the study. The Wilcoxon signed-rank test was used to
analyze intragroup changes in the numbers of immunoreactive-
positive cells in response to allergen. The Mann–Whitney U test
was used for intergroup comparisons. Correlation coefficients
were obtained by Spearman’s rank-order method. A p-value of
40.05 was accepted as non-significant (NS).
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